Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

rosuvastatin calcium

AstraZeneca AZ

AZ adds gout drug Zurampic to asset sale

Ironwood Pharmaceuticals buys exclusive US rights to the therapy and follow-up product

AstraZeneca AZ

AstraZeneca sets up genomics consortium for drug discovery

Will launch dedicated research centre to analyse data from clinical trials

- PMLiVE

Remicade safe from biosimilar competition this year, says J&J

Will defend the blockbuster’s US patents should Celltrion's Inflectra launch in 2016

- PMLiVE

GSK’s morality gene

The firm is mutating in important ways - we should watch carefully

AstraZeneca AZ

AZ gets $100m from Lilly as Alzheimer’s drug progresses

BACE inhibitor candidate displays ‘encouraging’ positive safety data

AstraZeneca AZ

AstraZeneca launches diabetes lifestyle campaign

Aims to support people with type 2 diabetes in becoming more active

- PMLiVE

GSK gene therapy tops CHMP recommendations

ADA-SCID treatment Strimvelis set for European approval

- PMLiVE

GSK unveils access plan for low-income countries

Will file patents for its drugs according to each country’s 'economic maturity'

- PMLiVE

India denies Vertex patent on cystic fibrosis drug Orkambi

Says treatment is neither innovative or more effective than its predecessor

- PMLiVE

Japanese approvals for GSK, AZ and Bayer

MHLW gives Nucala, Tagrisso and Xofigo the green light

Gilead Sciences

Gilead must pay just $200m for hep C patents, says jury

Merck & Co awarded a 4% royalty rate on sales of Sovaldi and Harvoni

- PMLiVE

Merck & Co wins hepatitis C patent dispute with Gilead

US jury upholds claim that Sovaldi and Harvoni infringe two sofosbuvir patents

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links